Company profile
Hyloris Pharmaceuticals
We add value through reinventing existing medicines for unmet patient needs worldwide
- Industry
- Biotechnology Research
- Employees
- 51
- Headquarters
- Liège, Walloon Region
- Founded
- 2012
- LinkedIn followers
- 10,410
- Office locations
- 1
Hyloris Pharmaceuticals company summary
Hyloris Pharmaceuticals is a company in the Biotechnology Research industry, headquartered in Liège, Walloon Region, founded in 2012. On LinkedIn the company has around 51 employees and 10,410 followers.
What technology does Hyloris Pharmaceuticals use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Hyloris Pharmaceuticals
Hyloris is a specialty pharma group focused on reinventing and optimizing existing medications through reformulation, repurposing and some smart NCEs developments to address important healthcare needs and deliver meaningful improvements for patients, healthcare professionals, and payors. Our development strategy primarily focuses on leveraging established regulatory pathways, such as the FDA’s 505(b)(2) pathway in the U.S., or equivalent regulatory frameworks in other regions, which are specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This approach can reduce the clinical and regulatory burden required for market entry, and significantly shorten development timelines, leading to reduced costs and risks. We announced a broad development portfolio of 28 products, including 25 value-added medicines of which two are currently in early stages of commercialization in collaboration with commercial partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. In addition to its core strategic focus, the Company has two high-barrier generic products approved in the U.S. and one additional high-barrier generic product in development. Beyond its announced portfolio, Hyloris has initiated several additional internal early-stage development activities, bringing the total pipeline to more than 30 products and product candidates, and continues to evaluate further product opportunities to support future growth. Where others stop, Hyloris starts and adds value through Reinventing Existing Medicines for unmet patient needs worldwide. Hyloris is based in Liège, Belgium and since 2020 listed on Euronext Brussels (EBR: HYL).
Where is Hyloris Pharmaceuticals located?
Hyloris Pharmaceuticals lists 1 location.
Compare companies similar to Hyloris Pharmaceuticals
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Hyloris Pharmaceuticals hyloris.com | Biotechnology Research | 51 | 2012 | Liège, Walloon Region |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Hyloris Pharmaceuticals
What does Hyloris Pharmaceuticals do?
Hyloris is a specialty pharma group focused on reinventing and optimizing existing medications through reformulation, repurposing and some smart NCEs developments to address important healthcare needs and deliver meaningful improvements for patients, healthcare professionals, and payors. Our development strategy primarily focuses on leveraging established regulatory pathways, such as the FDA’s 505(b)(2) pathway in the U.S., or equivalent regulatory frameworks in other regions, which are specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This approach can reduce the clinical and regulatory burden required for market entry, and significantly shorten development timelines, leading to reduced costs and risks. We announced a broad development portfolio of 28 products, including 25 value-added medicines of which two are currently in early stages of commercialization in collaboration with commercial partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. In addition to its core strategic focus, the Company has two high-barrier generic products approved in the U.S. and one additional high-barrier generic product in development. Beyond its announced portfolio, Hyloris has initiated several additional internal early-stage development activities, bringing the total pipeline to more than 30 products and product candidates, and continues to evaluate further product opportunities to support future growth. Where others stop, Hyloris starts and adds value through Reinventing Existing Medicines for unmet patient needs worldwide. Hyloris is based in Liège, Belgium and since 2020 listed on Euronext Brussels (EBR: HYL).
How many employees does Hyloris Pharmaceuticals have?
Hyloris Pharmaceuticals has around 51 employees on LinkedIn.
Where is Hyloris Pharmaceuticals headquartered?
Hyloris Pharmaceuticals is headquartered in Liège, Walloon Region.
When was Hyloris Pharmaceuticals founded?
Hyloris Pharmaceuticals was founded in 2012.
Build a lead list from companies like Hyloris Pharmaceuticals
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.